Cannabinoid hyperemesis syndrome in North America: evaluation of health burden and treatment prevalence

Abstract

Survey data suggest patients with CHS almost universally suffer from a cannabis use disorder, which has significant treatment implications. Treatment prevalence in the ED has increased substantially over a very short time period, with the highest rates seen during the Covid-19 pandemic.